Cytokeratin 10 Antibody / CK10 Antibody

Cytokeratin 10 Antibody Overview

Cytokeratin 10 Antibody reagents target keratin 10 (KRT10), a type I intermediate filament protein expressed in the suprabasal layers of stratified epithelia, especially in the skin. KRT10 pairs with keratin 1 to form heterodimers that stabilize the cytoskeleton, support cell differentiation, and maintain epidermal barrier function.

Mutations in KRT10 are associated with epidermolytic ichthyosis, a genetic disorder characterized by blistering and thickened skin due to keratinocyte fragility. Altered KRT10 expression is also observed in squamous cell carcinomas and other skin cancers. The Cytokeratin 10 Antibody is therefore essential in dermatology, epidermal biology, and oncology. The CK10 Antibody further supports applications in developmental biology, wound healing, and translational research.

Why Choose Cytokeratin 10 Antibodies from NSJ Bioreagents?

NSJ Bioreagents provides Cytokeratin 10 Antibodies validated for immunohistochemistry, immunofluorescence, western blotting, and ELISA. Each Cytokeratin 10 Antibody undergoes strict validation for specificity, reproducibility, and minimal cross-reactivity.

By selecting Cytokeratin 10 Antibodies from NSJ Bioreagents, researchers gain reagents optimized for clarity and reliability. Our antibodies provide strong staining in suprabasal keratinocytes, reproducible protein detection in lysates, and consistent results across experimental workflows. Detailed datasheets, positive controls, and validated protocols further support reproducibility in research and diagnostic settings.

Applications of Cytokeratin 10 Antibodies

The Cytokeratin 10 Antibody supports diverse applications in skin biology, pathology, and oncology.

1) Dermatology and Skin Biology

• Cytokeratin 10 Antibodies detect KRT10 in suprabasal keratinocytes.

• The Cytokeratin 10 Antibody supports studies of epidermal differentiation.

• CK10 Antibody reagents clarify keratinocyte maturation in normal and diseased skin.

2) Genetic Skin Disorders

• Cytokeratin 10 Antibodies identify KRT10 mutations linked to epidermolytic ichthyosis.

• The Cytokeratin 10 Antibody supports research into keratinopathies and inherited skin fragility.

• CK10 Antibody reagents validate biomarkers for genetic disorders of the epidermis.

3) Oncology and Tumor Biology

• Cytokeratin 10 Antibodies highlight expression changes in squamous cell carcinomas.

• The Cytokeratin 10 Antibody supports tumor classification in pathology workflows.

• CK10 Antibody reagents contribute to biomarker discovery in skin oncology.

4) Pathology and Diagnostics

• Cytokeratin 10 Antibodies confirm epithelial origin in dermatopathology.

• The Cytokeratin 10 Antibody provides diagnostic clarity in keratinizing versus non-keratinizing lesions.

• CK10 Antibody reagents support panels used in cancer diagnostics.

5) Developmental and Stem Cell Biology

• Cytokeratin 10 Antibodies track keratinocyte differentiation during embryogenesis.

• The Cytokeratin 10 Antibody validates suprabasal epithelial differentiation in organoid models.

• CK10 Antibody reagents support regenerative medicine involving skin repair.

6) Wound Healing and Tissue Repair

• Cytokeratin 10 Antibodies highlight keratinocyte behavior during re-epithelialization.

• The Cytokeratin 10 Antibody supports studies of epidermal regeneration under stress.

7) Translational and Clinical Research

• Cytokeratin 10 Antibodies are validated in biomarker-driven dermatology studies.

• The Cytokeratin 10 Antibody supports clinical trials focused on epidermal disorders.

• CK10 Antibody reagents provide reproducibility in translational medicine.

Why Are Cytokeratin 10 Antibodies Important?

KRT10 is a central keratin for suprabasal epidermal differentiation and barrier function. The Cytokeratin 10 Antibody provides precise detection of this protein, while the CK10 Antibody expands applications in diagnostics, oncology, and translational medicine.

In dermatology, Cytokeratin 10 Antibodies identify differentiation states and inherited keratinopathies. In oncology, the Cytokeratin 10 Antibody supports classification of squamous cell carcinomas. In developmental biology, CK10 Antibody reagents validate keratinocyte maturation in embryonic and regenerative contexts.

Clinically, KRT10 serves as both a biomarker for inherited disorders and a diagnostic marker in dermatopathology. Cytokeratin 10 Antibodies ensure reproducibility and diagnostic confidence, linking laboratory findings with patient care.

Conclusion

Cytokeratin 10 is a key suprabasal keratin with essential roles in skin biology, inherited disorders, and cancer. The Cytokeratin 10 Antibody equips scientists and clinicians with validated reagents for studying KRT10 in dermatology, oncology, and developmental biology, while the CK10 Antibody provides complementary support in translational medicine. By ensuring specificity and reproducibility, these antibodies remain indispensable for advancing keratin research and improving clinical outcomes.